The Excessive Daytime Sleepiness (EDS) Diagnosis Market comprises a range of diagnostic devices and software solutions aimed at accurately identifying and quantifying daytime sleepiness associated with disorders such as narcolepsy, obstructive sleep apnea, and shift-work sleep disorder. Core products include multiple sleep latency tests (MSLT), actigraphy monitors, home-based sleep analyzers, and cloud-enabled reporting platforms, each offering advantages in convenience, real-time data capture, and patient compliance. Innovations in wearable sensors allow continuous monitoring of sleep–wake patterns outside clinical settings, reducing the need for overnight stays in sleep labs and minimizing patient discomfort.

Software solutions powered by machine learning algorithms enhance diagnostic precision by analyzing large data sets, leading to earlier interventions and personalized treatment plans. Growing awareness of EDS’s link to road accidents and workplace productivity loss is fueling Excessive Daytime Sleepiness (EDS) Diagnosis Marketdemand for streamlined, non-invasive diagnostic workflows. Manufacturers are focusing on user-friendly interfaces, interoperability with electronic health records, and telehealth integration to address evolving market needs.

The excessive daytime sleepiness (EDS) diagnosis market is estimated to be valued at USD 7.44 billion in 2025 and is expected to reach USD 13.95 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.

Key Takeaways

Key players operating in the Excessive Daytime Sleepiness (EDS) Diagnosis Market are

·         Jazz Pharmaceuticals

·         Takeda Pharmaceutical Company

·         Harmony Biosciences

·         Avadel Pharmaceuticals

·         Bioprojet P.

Rising global prevalence of sleep disorders, coupled with increased investment in sleep health awareness campaigns, is boosting market opportunities for EDS diagnostic solutions. Employers and insurers are recognizing the cost savings tied to early detection of excessive sleepiness, leading to pilot programs in occupational health settings. Telemedicine adoption is transforming care pathways by enabling at-home sleep studies and virtual consults, aligning with key market trends toward decentralized diagnostics. Continuous technological enhancements have lowered per-test costs, making advanced diagnostics more accessible in emerging regions. Meanwhile, patient advocacy groups are lobbying for insurance coverage of non-invasive sleep tests, further fueling demand and business growth in underserved markets.

➢Get More Insights On: Excessive Daytime Sleepiness (EDS) Diagnosis Market

➢Get this Report in Japanese Language: 日中の過度の眠気EDS診断市場

➢Get this Report in Korean Language: 과도한주간졸음증EDS진단시장